GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EGEIRO Pharma (XPAR:ALVET) » Definitions » Total Receivables

EGEIRO Pharma (XPAR:ALVET) Total Receivables : €0.38 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is EGEIRO Pharma Total Receivables?

EGEIRO Pharma's Total Receivables for the quarter that ended in Dec. 2023 was €0.38 Mil.


EGEIRO Pharma Total Receivables Historical Data

The historical data trend for EGEIRO Pharma's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EGEIRO Pharma Total Receivables Chart

EGEIRO Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
0.47 0.18 0.33 0.28 0.38

EGEIRO Pharma Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 0.28 0.26 0.38 -

EGEIRO Pharma Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


EGEIRO Pharma Total Receivables Related Terms

Thank you for viewing the detailed overview of EGEIRO Pharma's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


EGEIRO Pharma Business Description

Traded in Other Exchanges
N/A
Address
Avenue Jean Mermoz 32/1, Gosselies, BEL, 6041
EGEIRO Pharma is a biopharmaceutical company. The company is focused on the clinical development of drugs for Idiopathic Pulmonary Fibrosis, a chronic, devastating, and fatal disease characterized by the deterioration of lung function.

EGEIRO Pharma Headlines

No Headlines